Is NMN permitted in the EU? NMN’s novel food status and that of NR explained

As of November 2026, NMN (nicotinamide mononucleotide) is an unauthorized novel food in the EU and therefore cannot be sold as a food supplement. However, authorization is imminent: On September 25, 2026, the relevant EU committee approved a draft allowing a specific β-NMN for adults up to 300 mg per day. Nicotinamide riboside chloride (NR), on the other hand, has been authorized since 2020.
- NMN is not on the EU Union list of authorized novel foods (as of November 2026).
- The EU committee endorsed the authorization on September 25, 2026, but a final decision has not yet been made.
- Nicotinamide riboside chloride has been authorized since January 13, 2020, at a dosage of up to 300 mg per day (pregnant and breastfeeding women: 230 mg).
You read about NMN in health magazines, hear it mentioned in podcasts, and see various products in online shops. But have you ever wondered whether NMN has actually been authorized in the EU? An important term for such cases that hardly anyone knows, but which determines the fate of every molecule in your capsule, is Novel Food. Here you will find the current status, the sources, and instructions on how you can check the status yourself. How NAD+ works in the body is explained in our basic article What is NAD+?
What does "Novel Food" mean?
A novel food is a food or ingredient that was not consumed in the EU to a significant extent before May 15, 1997. Such substances may only be sold once they have been authorized under the Novel Food Regulation (EU) 2015/2283.
The path to authorization is long. A manufacturer submits an application, the European Food Safety Authority (EFSA) assesses its safety, and then the Member States vote in a committee. Finally, the Commission adds the substance to the Union list, specifying the exact conditions under which it may be used in foods, for which groups of people, in what daily amount, and what information must be provided on the label.
How does it differ from regular food supplements? These do not require authorization, only notification to the authorities. However, a novel active ingredient within them does require approval. If it is not on the list, the product cannot be placed on the market.
Is nicotinamide riboside (NR) authorized in the EU?
Yes, nicotinamide riboside chloride has been authorized as a novel food in the EU since January 13, 2020, under Implementing Regulation (EU) 2020/16. The current conditions are now set out in Implementing Regulation (EU) 2022/1160.
Food supplements containing up to 300 mg of NR chloride per day for adults and up to 230 mg for pregnant and breastfeeding women are permitted. This is based on the EFSA opinion of 2019, which assessed these amounts as safe. The original applicant's data protection expired on February 20, 2025. Since then, other manufacturers have also been allowed to use NR chloride according to the specified standard.
One detail that matters when buying: The chloride salt is authorized. Other NR salts are not on the Union list. You can find more about the form on our page about nicotinamide riboside (NR).
Is NMN authorized in the EU?
No, as of November 2026, NMN is not yet authorized in the EU. The Commission's novel food catalogue lists NMN as an unauthorized novel food, and it has not yet been included on the Union list.
That this is no mere formality is demonstrated by a case from Bavaria. The Administrative Court of Würzburg upheld a sales ban on NMN products from an online retailer on March 10, 2021. The classification as a "chemical" changed nothing: If you swallow it, you are consuming a food, not a "chemical substance".
Now things are moving. In May 2026, the EFSA published its opinion on β-NMN. On September 25, 2026, the relevant committee of Member States approved authorization draft D118035/02.
The draft allows β-NMN only in food supplements, only for adults, and only up to 300 mg per day, with a mandatory label statement. The original applicant's data protection lasts for five years; NMN from other manufacturers will remain unauthorized for sale without its own authorization. The regulation has not yet entered into force.
A second NMN procedure (NF 2025/35790) was concluded by the Commission in 2026 without inclusion in the Union list. Authorization therefore does not apply to "NMN" in general, but to a specific substance from a specific manufacturing process.
NMN, NR and NAD+: status overview
Authorization status in the EU, as of November 11, 2026
| Substance | Status in the EU | Legal basis | Maximum daily amount in food supplements |
|---|---|---|---|
| Nicotinamide riboside chloride (NR) | Authorized since January 13, 2020 | Implementing Regulation (EU) 2020/16, now Implementing Regulation (EU) 2022/1160 | 300 mg (adults), 230 mg (pregnant and breastfeeding women) |
| β-NMN | Not yet authorized; committee approved on September 25, 2026; publication pending | Draft D118035/02; EFSA opinion 2026 | Planned: 300 mg, adults only, not for pregnant and breastfeeding women |
| NMN from other manufacturers | Not authorized | 5 years of data protection for the original applicant after authorization | Not authorized for sale |
| Other NR salts | Not on the Union list | None | Not authorized for sale |
| NAD+ | According to the novel food catalogue, not novel in food supplements | Catalogue entry POL-NF-09841 | No novel food maximum amount |
Result: Of the NAD+ precursors, only nicotinamide riboside chloride is currently authorized as a novel food in the EU.
What does this mean for you as a buyer?
Anyone selling NMN as a food supplement in the EU today is operating outside the novel food regulations. The authorities can remove such products from the market, and there is no tested specification for purity and dosage.
It is simpler with NR. Look for the designation "nicotinamide riboside chloride", a maximum of 300 mg per day, and a test report from an accredited laboratory. You can read how NR and NMN differ in the body in NR vs. NMN: What is the difference?.
Which NR products deliver to Austria and how they differ in dosage, laboratory report, and price is shown in our comparison of NAD+ supplements for Austria.
And in Switzerland?
In Switzerland, the Federal Office of Food Safety and Veterinary Affairs (BLV) authorizes novel foods under its own regulations. We have not found a BLV decision specifically on NMN as of November 10, 2026. Before buying, check the BLV page on the authorization of novel foods.
How to check the status yourself
You do not have to rely on shops or forums. Four public sources are sufficient:
- Novel Food Catalogue: Search for the substance name in the Commission catalogue. It shows whether a substance is considered novel.
- Union list: The consolidated version of Implementing Regulation (EU) 2017/2470 on EUR-Lex contains every authorized substance with maximum amounts.
- Official Journal: A search for "nicotinamide mononucleotide" on EUR-Lex shows whether the NMN regulation has been published.
- Comitology register: It shows the status of draft D118035 with the date of the vote.
We will update this article as soon as the NMN regulation is published in the Official Journal.
Why REVIVE uses NR chloride
REVIVE by Never Age Nutrition contains 250 mg of nicotinamide riboside chloride per daily dose, within the EU-authorized form and amount of NR.
Never Age Nutrition therefore uses an NAD+ precursor whose safety has been assessed by the EFSA and whose status in the EU has been established since 2020. REVIVE combines this with four other nutrients from longevity research—namely calcium alpha-ketoglutarate, quercetin, betaine, and selenium—in a capsule routine.
REVIVE by Never Age Nutrition from Vienna is tested for heavy metals and microbiology by a DAkkS-accredited laboratory in Germany. We explain which studies support all five ingredients in REVIVE Ingredients: The Research Behind Them.
REVIVE NAD+ Booster
- ✓250 mg nicotinamide riboside chloride (NR) per daily dose
- ✓With calcium AKG, quercetin, betaine and selenium
- ✓Tested by Limbach Analytics (DAkkS-accredited)
- ✓Vegan · made in the EU
- ✓Just 2 capsules a day
€49,90
Discover now →Frequently asked questions about NMN and the novel food status
Sources
- Regulation (EU) 2015/2283 on novel foods. EUR-Lex. https://eur-lex.europa.eu/eli/reg/2015/2283/oj (accessed November 10, 2026)
- Implementing Regulation (EU) 2017/2470 (Union list of novel foods), consolidated version of August 10, 2026. EUR-Lex. https://eur-lex.europa.eu/eli/reg_impl/2017/2470 (accessed November 10, 2026)
- Implementing Regulation (EU) 2020/16 on the authorization of nicotinamide riboside chloride. EUR-Lex. https://eur-lex.europa.eu/legal-content/DE/TXT/HTML/?uri=CELEX:32020R0016 (accessed November 10, 2026)
- Implementing Regulation (EU) 2022/1160 (current conditions for NR chloride). EUR-Lex. https://eur-lex.europa.eu/legal-content/DE/TXT/HTML/?uri=CELEX:32022R1160 (accessed November 10, 2026)
- Directive 2002/46/EC on food supplements, Annex II (consolidated). EUR-Lex. https://eur-lex.europa.eu/eli/dir/2002/46 (accessed November 10, 2026)
- EFSA NDA Panel (2026). Safety of beta-nicotinamide mononucleotide (β-NMN) as a novel food. EFSA Journal 24(5): e10007. https://doi.org/10.2903/j.efsa.2026.10007 (accessed November 10, 2026)
- EFSA NDA Panel (2019). Safety of nicotinamide riboside chloride as a novel food. EFSA Journal 17(8): 5775. https://doi.org/10.2903/j.efsa.2019.5775 (accessed November 10, 2026)
- Comitology Register: Draft D118035/02, authorisation of β-NMN as a novel food. European Commission. https://ec.europa.eu/transparency/comitology-register/screen/documents/118035/2/consult (accessed 10 November 2026)
- Concluded Novel Food Procedures, including NF 2025/35790 (NMN). European Commission. https://food.ec.europa.eu/food-safety/novel-food/decisions-terminating-procedure_en (accessed 10 November 2026)
- Novel Food Catalogue: Entries on NMN and NAD+. European Commission. https://ec.europa.eu/food/food-feed-portal/screen/novel-food-catalogue/search (accessed 10 November 2026)
- VG Würzburg, Decision of 10 March 2021, W 8 S 21.258. gesetze-bayern.de. https://www.gesetze-bayern.de/Content/Document/Y-300-Z-BECKRS-B-2021-N-6987 (accessed 10 November 2026)
- Yang W et al. (2026). Safety and metabolism-related outcomes of oral NMN: systematic review and meta-analysis. Nutrients 18: 2251. https://doi.org/10.3390/nu18142251 (accessed 10 November 2026)
- Authorisation of novel foods. BLV, Switzerland. https://www.blv.admin.ch/de/bewilligung-neuartige-lebensmittel (accessed 10 November 2026)
Food supplements are not a substitute for a varied and balanced diet and a healthy lifestyle. Do not exceed the stated recommended daily dose. Keep out of reach of young children. This article does not replace medical advice.
